Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...
Fra Aller Medias regnskab for 2023/24 bemærker vi følgende forhold: Driftsresultatet (EBITDA) blev markant forbedret i ...
“Our imprint is now truly global. Our impact is now truly profound. Our blind assault on the planet has finally come to alter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback